FIELD: medicine, oncology, molecular biology. SUBSTANCE: invention relates to method of identification of genes with site-specific or site-preferable expression in target-cells that have been detected and isolated preliminary by multiple procedures using immunomagnetic method. Then the purified target-cells are subjected for the known cloning procedures. Malignant cells, for example, metastatic cells, are preferable target-cells. Method of differential image or method of subtractive hybridization can be used for genes cloning. EFFECT: enhanced precision of identification. 11 cl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR ELIMINATING UNDESIRABLE TARGET CELLS | 1997 |
|
RU2182493C2 |
| METHOD OF INHIBITING MIGRATION OF CANCER CELLS | 2006 |
|
RU2404805C2 |
| CANCER TREATMENT USING TARGETED ANTIBODIES IN VIVO | 2011 |
|
RU2642305C2 |
| PDGFRα ANTIBODIES FOR TREATING SECONDARY BONE TUMOUR | 2006 |
|
RU2502523C2 |
| RECEPTOR ANTAGONISTS FOR TREATING METASTATIC CANCER | 2009 |
|
RU2455026C2 |
| AXL SIGNALLING INHIBITION IN ANTIMETASTATIC THERAPY | 2011 |
|
RU2556822C2 |
| METHOD OF EARLY MOLECULAR-BIOLOGICAL DIAGNOSIS OF MALIGNANT GROWTHS AND AMYOTROPHIC LATERAL SCLEROSIS | 2018 |
|
RU2706714C1 |
| METHOD OF USING AXL AS MARKER OF EPITHELIAL-MESENCHYMAL TRANSITION | 2010 |
|
RU2586493C2 |
| METHOD OF IN VITRO DETERMINATION OF PROGNOSIS OF DISEASE DEVELOPMENT IN PATIENT WITH CANCER AND METHOD OF IN VITRO MONITORING EFFECT OF THERAPY ADMINISTERED TO PATIENT WITH CANCER | 2006 |
|
RU2434946C2 |
| IMMUNITY INDUCING AGENT | 2013 |
|
RU2639518C2 |
